Details.
Provides assistance for Combivir, Cabenuva, Dovato, Epivir, Epzicom, Juluca, Lexiva, Prezcobix, Retrovir, Rukobia, Selzentry, Tivicay and Tivicay PD, Triumeq and Triumeq PD, Trizivir, Viracept, and Ziagen to eligible individuals with income at or below 500% FPL. Eligibility also requires uninsured status or no prescription drug coverage, with specified exceptions for certain Medicare or private insurance situations. New applications were no longer accepted for several listed products as of July 2022.